Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 8/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | GBA1 | P04062 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6467494 | 1.00 | FUCA1 (0.56) | FUCA1LMNAAPPGBA1 | |
| SCHEMBL12997414 | 1.00 | FUCA1 (0.56) | FUCA1LMNAAPPGBA1 | |
| SCHEMBL11921704 | 1.00 | FUCA1 (0.56) | FUCA1LMNAAPPGBA1 | |
| SCHEMBL18895855 | 1.00 | FUCA1 (0.56) | FUCA1LMNAAPPGBA1 | |
| SCHEMBL19387819 | 1.00 | FUCA1 (0.56) | FUCA1LMNAAPPGBA1 | |
| SCHEMBL11886528 | 1.00 | FUCA1 (0.56) | FUCA1LMNAAPPGBA1 | |
| SCHEMBL14079823 | 1.00 | FUCA1 (0.56) | FUCA1LMNAAPPGBA1 | |
| SCHEMBL12986895 | 1.00 | FUCA1 (0.56) | FUCA1LMNAAPPGBA1 | |
| SCHEMBL16664828 | 0.95 | FUCA1 (0.53) | FUCA1LMNAAPPGBA1 | |
| SCHEMBL12568579 | 0.95 | FUCA1 (0.50) | FUCA1LMNAAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158165-A1 | Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-9238726-B2 | Molded article comprising polypropylene resin composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-01-19 | — | — | US | disclosed |
| US-20130189462-A1 | MOLDED ARTICLE COMPRISING POLYPROPYLENE RESIN COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158165-A1 | Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders | APP, SNCA, MAPT | FUCA1 1012/4885LMNA 3481/4885APP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.